stockrow
Friday 6 November 2026
Export VRDN’s income statement to Excel — free account
Viridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
28.50
0.05
−0.18%
Follow VRDN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
37.25 | 28.19 | 27.86 | 84.43 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(111.10) | (16.71) | (18.82) | (23.94) | |
P/B ratio |
4.47 | 3.97 | 3.51 | 3.94 | |
Price to Tangible BV |
4.47 | 3.97 | 3.58 | 4.01 | |
EV/Sales |
25.73 | 18.27 | 17.59 | 57.65 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.59) | (4.27) | (3.75) | (4.44) | |
EV/FCF |
(6.58) | (4.27) | (3.73) | (4.42) | |
Quick Ratio |
12.37 | 14.71 | 16.56 | 13.64 | |
Current Ratio |
12.65 | 15.15 | 16.95 | 14.46 | |
Net Debt/EBITDA |
6.63 | 6.04 | 5.79 | 9.12 | |
Debt/Assets |
5.55% | 6.39% | 22.07% | 0.00% | |
Debt/Equity |
0.07 | 0.08 | 0.37 | 0.00 | |
Asset Turnover |
0.09 | 0.10 | 0.08 | 0.03 | |
Operating CF/Net income |
0.20 | 1.14 | 0.83 | 0.92 | |
Capex/Depreciation |
0.15 | 0.01 | 0.98 | 0.31 | |
Interest Coverage |
(36.93) | (33.56) | (15.20) | — | |
Research and Development Expense of Revenue |
67,581.06% | 55,057.45% | 25,203.17% | 272.18% | |
Selling, General and Administrative Expense of Revenue |
25,510.61% | 27,431.91% | 19,357.39% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
9,082.58% | 9,496.45% | 5,980.28% | 66.92% | |
Graham Net Nets |
0.27 | 0.32 | 0.33 | 0.25 | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(10.57%) | (16.97%) | (18.35%) | (16.37%) | |
Free Cash Flow Yield |
(10.49%) | (15.20%) | (16.91%) | (15.46%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.28) | (1.17) | (0.98) | 0.00 | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.28) | (1.17) | (0.99) | 0.00 | |
Cash per Share |
10.31 | 7.46 | 9.10 | 0.00 | |
Shareholders Equity per Share |
8.52 | 6.22 | 6.14 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
8.52 | 6.22 | 6.14 | 0.00 | |
Free Cash Flow |
(23.99) | (119.68) | (106.63) | (93.14) | |
Working Capital |
823.54 | 732.94 | 1,017.48 | 943.08 | |
Capital Expenditures |
(0.24) | (0.02) | (1.31) | (0.37) | |
Net Current Asset Value |
716.98 | 631.74 | 646.13 | 565.16 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
1.82 | 0.16 | 4.60 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 37.55 | — | |
Average Payables |
5.41 | 8.60 | 8.59 | 9.68 | |
Average Assets |
820.91 | 725.00 | 839.78 | 802.90 | |
Average Common Equity |
536.43 | 459.77 | 445.18 | — |
Columns are period end dates · fundamentals updated 4 Nov 2026